MaxCyte | DEF 14A: Definitive information statements
Apr 26 17:22 ET
MaxCyte | 8-K: MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance
Mar 12 16:15 ET
MaxCyte | 8-K: Current report
Mar 5 16:21 ET
MaxCyte | 8-K: Current report
Jan 26 16:50 ET
MaxCyte | 8-K: MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results
Jan 8 00:00 ET
MaxCyte | 8-K: Current report
Dec 11, 2023 16:30 ET
MaxCyte | 8-K: MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance
Nov 8, 2023 16:12 ET
MaxCyte | 8-K: Current report
Oct 4, 2023 16:14 ET
MaxCyte | 8-K: MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance
Aug 9, 2023 16:16 ET
MaxCyte | 8-K: Current report
Jun 23, 2023 09:27 ET
MaxCyte | 8-K: MaxCyte Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Guidance
May 10, 2023 16:14 ET
MaxCyte | DEF 14A: Definitive proxy statements
Apr 28, 2023 16:22 ET
MaxCyte | 8-K: Current report
Mar 28, 2023 09:40 ET
MaxCyte | 8-K: Current report
Mar 15, 2023 16:15 ET
MaxCyte | 8-K: MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue Results and Provides 2023 Revenue Guidance
Mar 6, 2023 17:04 ET
MaxCyte | 8-K: Current report
Dec 1, 2022 08:30 ET
MaxCyte | 8-K: MaxCyte Reports Third Quarter 2022 Financial Results 22% Year-Over-Year Core Business Revenue Growth in Third Quarter 2022 Reiterates 2022 Revenue Guidance
Nov 9, 2022 16:15 ET
MaxCyte | 8-K: MaxCyte Reports Second Quarter and Half-Year 2022 Financial Results 45% Year-Over-Year Core Business Revenue Growth in Second Quarter 2022 Raises 2022 Core Revenue Growth Guidance to Approximately 30%
Aug 10, 2022 16:15 ET
MaxCyte | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Jul 14, 2022 16:37 ET
MaxCyte | 8-K: Current report
Jun 30, 2022 16:44 ET
No Data
No Data